Schrodinger is a heavyweight in computational drug discovery, combining physics-based molecular simulations with machine learning to accelerate the identification and optimization of drug candidates. Their platform, anchored by the FreeEnergy Perturbation (FEP+) technology and the Maestro molecular modeling suite, is widely regarded as industry-leading for structure-based drug design. The integration of AI/ML models with rigorous quantum mechanics calculations gives it a significant edge over purely data-driven competitors. Schrodinger serves major pharma companies and has its own internal drug pipeline, which speaks to confidence in the platform's capabilities. The API availability enables integration into existing research workflows, though the learning curve is steep for non-computational chemists. The custom enterprise pricing puts it out of reach for smaller teams and academic labs without institutional licenses, which is a notable barrier. Documentation is extensive but can feel overwhelming. Overall, Schrodinger represents the gold standard in physics-informed AI drug discovery, though accessibility and cost remain limiting factors for broader adoption.